ISSN 1948-5182 (online)

World Journal of *Hepatology*

Monthly Volume 17 Number 11 November 27, 2025

Published by Baishideng Publishing Group Inc

World Journal of Hepatology

Contents

Monthly Volume 17 Number 11 November 27, 2025

EDITORIAL

Madian A. Essential phospholipids and enzyme-based staging in nonalcoholic fatty liver disease: A call to action. *World J Hepatol* 2025; 17(11): 110725 [DOI: 10.4254/wjh.v17.i11.110725]

Hori T. Impact of alcohol-associated and metabolic dysfunction-associated steatotic liver diseases upon hepatic disorder and carcinogenesis in the current era. *World J Hepatol* 2025; 17(11): 112359 [DOI: 10.4254/wjh.v17.i11.112359]

REVIEW

Akbulut S, Colak C. Explainable artificial intelligence and ensemble learning for hepatocellular carcinoma classification: State of the art, performance, and clinical implications. *World J Hepatol* 2025; 17(11): 109494 [DOI: 10.4254/wjh.v17.i11.109494]

Abdalla MMI, Ismail-Khan M. Liver as a metabolic sensor in gestational diabetes: Implications for offspring's liver and diabetes risk. *World J Hepatol* 2025; 17(11): 110185 [DOI: 10.4254/wjh.v17.i11.110185]

Kumar G, Shah YR, Shahzad A, Jameel K, Guevara-Lazo D, Khan NA, Dahiya DS, Gangwani MK, Ravichandran R, Patel R, Hayat U, Thandassery RB. Genetic predeterminants and recent advancements in steatotic liver disease: A roadmap toward precision hepatology. *World J Hepatol* 2025; 17(11): 111576 [DOI: 10.4254/wjh.v17.i11.111576]

Guerrero-Guerrero R, Mendez-Guerrero O, Carranza-Carrasco A, Tejeda F, Ardon-Lopez A, Navarro-Alvarez N. Beyond bones: Revisiting the role of vitamin D in chronic liver disease. *World J Hepatol* 2025; 17(11): 112315 [DOI: 10.4254/wjh.v17.i11.112315]

Zhang CY, Liu S, Sui YX, Yang M. Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis. *World J Hepatol* 2025; 17(11): 113756 [DOI: 10.4254/wjh.v17.i11.113756]

MINIREVIEWS

Li MJ, Wen CL, Cheng HT, Lyu HN, Han YY. PANoptosis in hepatocellular carcinoma: Underlying mechanisms. *World J Hepatol* 2025; 17(11): 109051 [DOI: 10.4254/wjh.v17.i11.109051]

Fiore M, Cosenza G, Coppolino F, Pota V, Sansone P, Petrou S, Pace MC. Hypertransaminasemia in non-cirrhotic critically-ill patients. *World J Hepatol* 2025; 17(11): 109645 [DOI: 10.4254/wjh.v17.i11.109645]

Zhao YH, Leng SS, Wang Y, Kui FZ, Gan W. Non-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease. *World J Hepatol* 2025; 17(11): 110080 [DOI: 10.4254/wjh.v17.i11.110080]

Li ZY, Xie C, Cai HQ. Pre-transplant downstaging strategies for hepatocellular carcinoma with portal vein tumor thrombus: Current therapies and future challenges. *World J Hepatol* 2025; 17(11): 110614 [DOI: 10.4254/wjh.v17.i11.110614]

Bessone F, Bjornsson ES. Autoimmune-like hepatitis induced by drugs: Still many unanswered questions. *World J Hepatol* 2025; 17(11): 110946 [DOI: 10.4254/wjh.v17.i11.110946]

Hegazy MAE. Artificial intelligence in metabolic dysfunction-associated steatotic liver disease: Machine learning for non-invasive diagnosis and risk stratification. *World J Hepatol* 2025; 17(11): 111354 [DOI: 10.4254/wjh.v17.i11.111354]

Correa TL, Duong N. Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes. *World J Hepatol* 2025; 17(11): 112573 [DOI: 10.4254/wjh.v17.i11.112573]

Liu ZH, Wang WJ, Dang SS. Early screening for liver cancer must be performed. *World J Hepatol* 2025; 17(11): 112675 [DOI: 10.4254/wjh.v17.i11.112675]

ORIGINAL ARTICLE

Case Control Study

Ichikawa T, Miuma S, Yamashima M, Yamamichi S, Koike M, Nakano Y, Yajima H, Miyazaki O, Ikeda T, Okamura T, Komatsu N, Yoshino M, Miyaaki H. Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease. *World J Hepatol* 2025; 17(11): 110698 [DOI: 10.4254/wjh.v17.i11.110698]

Retrospective Cohort Study

Abdel Hafez RS, Semeya AA, Elgamal R, Othman AA. Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study. *World J Hepatol* 2025; 17(11): 110638 [DOI: 10.4254/wjh.v17.i11.110638]

Wang LJ, Cui Y, Huang LF, Zhang JQ, Zhao TT, Wang HW, Liu M, Jin KM, Wang K, Xing BC. Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma. *World J Hepatol* 2025; 17(11): 112364 [DOI: 10.4254/wjh.v17.i11.112364]

Retrospective Study

Lin DX, Zhuo XB, Chang GJ, Lei WD, Huang J, Zhang Y, Qiu ZJ, Zhang SY. Laparoscopic *vs* open surgery for complex hepatolithiasis: A retrospective comparative study. *World J Hepatol* 2025; 17(11): 110050 [DOI: 10.4254/wjh.v17.i11.110050]

Observational Study

Corrêa FCCR, Nader ISTP, Riolino MRS, Silva E. Intra-rater reliability of the 6-min walk test in people with liver cirrhosis. *World J Hepatol* 2025; 17(11): 110331 [DOI: 10.4254/wjh.v17.i11.110331]

Alalwani J, Derbala M, Tayyem R, Bassil M. Metabolic associated steatotic liver disease in Qatar: Analysis of dietary patterns and nutrient intake. *World J Hepatol* 2025; 17(11): 111995 [DOI: 10.4254/wjh.v17.i11.111995]

Zhang DY, Li D, Huang SM, Chen C, Zeng F, Bai FH. Epidemiology and clinical features of alcoholic liver disease in Hainan Province, China. *World J Hepatol* 2025; 17(11): 112430 [DOI: 10.4254/wjh.v17.i11.112430]

LETTER TO THE EDITOR

Cui X, Liang Z. Association between metabolic dysfunction-associated steatotic liver disease, vitamin D3, and diabetic gastric motility disorders in type 2 diabetes mellitus. *World J Hepatol* 2025; 17(11): 112060 [DOI: 10.4254/wjh.v17.i11.112060]

Koriem KMM. Tumor necrosis factor alpha-induced protein 3: Biomarker discovery and therapeutic advancement in primary biliary cholangitis. *World J Hepatol* 2025; 17(11): 112679 [DOI: 10.4254/wjh.v17.i11.112679]

World Journal of Hepatology

Monthly Volume 17 Number 11 November 27, 2025

Contents

ABOUT COVER

Editorial Board Member of *World Journal of Hepatology*, Shahinul Alam, MD, Professor, Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka 1000, Bangladesh. shahinul67@yahoo.com

AIMS AND SCOPE

The primary aim of *World Journal of Hepatology* (*WJH*, *World J Hepatol*) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (ESCI), Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2025 Edition of Journal Citation Reports® cites the 2024 journal impact factor (JIF) for *WJH* as 2.5; JIF Quartile: Q2. The *WJH*'s CiteScore for 2024 is 4.8 and Scopus CiteScore rank 2024: Hepatology is 38/87.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Yan-Liang Zhang*; **Production Department Director:** *Xiang Li*; **Cover Editor:** *Xiang Li*.

NAME OF JOURNAL
World Journal of Hepatology

ISSN
ISSN 1948-5182 (online)

LAUNCH DATE
October 31, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Nikolaos T Pyrsopoulos, Ke-Qin Hu, Joseph K Lim

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF
Shuang-Suo Dang

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/1948-5182/editorialboard.htm

PUBLICATION DATE
November 27, 2025

COPYRIGHT
© 2025 Baishideng Publishing Group Inc

PUBLISHING PARTNER
Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

POLICY OF CO-AUTHORS
https://www.wjgnet.com/bpg/GerInfo/310

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/GerInfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

PUBLISHING PARTNER's OFFICIAL WEBSITE
http://2yuan.xjtu.edu.cn/Html/Departments/Main/Index_21148.html

© 2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

E-mail: office@baishideng.com https://www.wjgnet.com

World Journal of Hepatology

Submit a Manuscript: https://www.f6publishing.com

World J Hepatol 2025 November 27; 17(11): 111354

DOI: 10.4254/wjh.v17.i11.111354

ISSN 1948-5182 (online)

MINIREVIEWS

Artificial intelligence in metabolic dysfunction-associated steatotic liver disease: Machine learning for non-invasive diagnosis and risk stratification

Mona Abd-Elmonem Hegazy

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade B, Grade C, Grade C

Novelty: Grade B, Grade C, Grade C

Creativity or Innovation: Grade C, Grade C, Grade C

Scientific Significance: Grade B, Grade C, Grade C

P-Reviewer: Boteon YL, MD, PhD, Full Professor, Brazil; Sun JZ, Chief, Professor, China

Received: June 30, 2025

Revised: July 26, 2025

Accepted: October 27, 2025

Published online: November 27, 2025

Processing time: 152 Days and 14.3 Hours

Mona Abd-Elmonem Hegazy, Department of Internal Medicine, Division of Hepatology and Gastroenterology, Kasr Aliny Hospital, Faculty of Medicine, Cairo University, Cairo 12556, Egypt

Corresponding author: Mona Abd-Elmonem Hegazy, MD, Department of Internal Medicine, Division of Hepatology and Gastroenterology, Kasr Aliny Hospital, Faculty of Medicine, Cairo University, Kasr Alainy Street, Garden City, Cairo 12556, Egypt. monahegazy@cu.edu.eg

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, represents a growing global health burden, contributing significantly to liver-related morbidity and mortality. Early detection and timely intervention are essential to prevent disease progression. Conventional diagnostic methods, which rely on specialized imaging and invasive liver biopsies, underscore the need for non-invasive, cost-effective alternatives. Artificial intelligence—particularly machine learning and deep learning—has emerged as a transformative tool in MASLD diagnostics, offering improved accuracy in risk prediction, imaging interpretation, and disease stratification. This review synthesizes recent advancements in AI-based MASLD diagnostics, highlighting key models, performance metrics, and clinical applications, while addressing ongoing challenges such as data standardization, interpretability, and clinical validation.

Key Words: Metabolic dysfunction-associated steatotic liver disease; Machine learning; Deep learning; Risk prediction; Disease stratification

©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Artificial intelligence (AI), machine learning and deep learning, holds transformative potential for the non-invasive diagnosis and risk stratification of metabolic dysfunction-associated steatotic liver disease (MASLD). These AI models utilize readily available clinical data, biomarkers, and imaging modalities (ultrasound, computed tomography, magnetic resonance imaging) to detect steatosis, predict disease risk, and stage fibrosis with greater accuracy than conventional scoring systems such as fibrosis-4. Despite their promising performance, several challenges hinder widespread clinical adoption, including the need for data standardization, rigorous prospective validation, model interpretability, and seamless integration into existing healthcare workflows. Overcoming these barriers is essential to fully harness AI potential in improving MASLD diagnosis and management.

Citation: Hegazy MAE. Artificial intelligence in metabolic dysfunction-associated steatotic liver disease: Machine learning for non-invasive diagnosis and risk stratification. *World J Hepatol* 2025; 17(11): 111354
URL: https://www.wjgnet.com/1948-5182/full/v17/i11/111354.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i11.111354

INTRODUCTION

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disorder worldwide, affecting approximately 30% of the general adult population and up to 70% of individuals with obesity or type 2 diabetes mellitus (T2DM)[1]. MASLD encompasses a disease spectrum ranging from simple steatosis to metabolic steatohepatitis, fibrosis, and cirrhosis, and is associated with increasing morbidity and healthcare costs[2]. Early diagnosis and accurate risk stratification are critical to prevent disease progression; however, current diagnostic approaches—such as magnetic resonance imaging (MRI)-proton density fat fraction (MRI-PDFF) and liver biopsy—are costly, invasive, or inaccessible in many resource-limited settings. Therefore, the development of innovative, non-invasive strategies for disease detection, risk assessment, and management is urgently needed[3].

Artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), has emerged as a promising solution, offering non-invasive, scalable, and accurate tools for the diagnosis, staging, and prognostication of MASLD. AI algorithms can integrate clinical data (*e.g.*, electronic health records), biomarkers, and imaging modalities (*e.g.*, ultrasound, MRI) to outperform traditional risk scores such as the fibrosis-4 (FIB-4) index[3]. This mini-review provides a concise yet comprehensive overview of current AI applications in MASLD diagnosis. It also discusses key challenges and limitations in translating AI into clinical practice, including issues related to data privacy, model interpretability, and the need for robust prospective validation. The aim is to inform clinicians, researchers, and policymakers on the practical implications of integrating AI technologies into MASLD management.

AI IN MASLD DIAGNOSIS: MACHINE LEARNING AND DEEP LEARNING APPROACHES

Several studies have investigated predictive scoring systems and risk factors for MASLD; however, their findings remain inconsistent and controversial[4,5]. ML offers a promising alternative for identifying optimal predictive models[6], as it enables the algorithms construction that learn from data without being explicitly programmed. Applications of ML in gastroenterology field are steadily expanding[7].

ML algorithms analyze anthropometric, demographic, and biochemical data to predict MASLD risk, and numerous studies have demonstrated their effectiveness through various modeling approaches. Yu *et al*[3] developed an explainable random forest (RF) model incorporating 10 clinical features, including liver enzymes, body mass index (BMI), and metabolic markers. The model achieved excellent performance, with an area under the curve (AUC) of 0.928 in internal validation and 0.918 in external cohorts. Among six evaluated ML models, the RF algorithm demonstrated the highest discriminative ability, making it the preferred choice. The final model showed excellent calibration and discrimination, using only routinely collected clinical data.

Another ML approach using support vector machines (SVM) was employed to assess liver fibrosis without relying on elastography or platelet counts, achieving AUCs of 0.886 for ≥ F2 fibrosis, 0.882 for ≥ F3, and 0.916 for cirrhosis detection [8]. Comparative studies by Ahn *et al*[6] and Spann *et al*[7] have shown that ML models often outperform conventional risk scores (*e.g.*, FIB-4, APRI) by integrating a broader range of clinical variables.

DL, a subset of AI, is particularly valuable for imaging analysis. Convolutional neural networks (CNNs), a prominent DL architecture, have enhanced the diagnostic accuracy of imaging based MASLD assessment. For instance, CNNs employing transfer learning applied to ultrasound images have achieved an AUC of 0.91 for detecting hepatic steatosis (defined as PDFF ≥ 5%)[9]. Additionally, computed tomography (CT) and MRI have been utilized for DL-based analysis. Yasaka *et al*[10] demonstrated moderate accuracy in fibrosis staging using a CT-based DL model, although further refinement is needed before widespread clinical application.

INTEGRATION OF AI WITH NON-INVASIVE DIAGNOSTIC TOOLS

AI models in MASLD utilize a wide range of data inputs, including clinical parameters (*e.g.*, body mass index, diabetes status), laboratory results (*e.g.*, liver enzymes, lipid profiles), imaging features (ultrasound, CT, MRI), and histology-confirmed outcomes. The integration of these multimodal data sources enhances predictive accuracy; however, variability in data acquisition remains a significant challenge (Table 1).

AI algorithms that incorporate elastography data have shown improved performance in fibrosis detection by analyzing liver stiffness measurements[11]. Multimodal data integration—combining demographic, clinical, anthropometric, and biochemical variables—enables more accurate population-level risk prediction[2]. AI plays a crucial role in fusing clinical, imaging, and laboratory data to enhance diagnostic precision and improve overall performance of non-invasive assessments[6].

DATA ACQUISITION HETEROGENEITY

While advanced healthcare centers often benefit from automated extraction of data from electronic health records (EHRs) and picture archiving and communication systems (PACS)—including digital imaging and communications in medicine (DICOM) files and laboratory application programming interfaces[2,11]—manual data entry is still required for non-digitized sources such as histopathology reports and calculated clinical scores (*e.g.*, APRI, FIB-4)[8,10]. The adoption of standardized data pipelines, such as Fast Healthcare Interoperability Resources for EHRs and AI-ready DICOM annotations, is essential for achieving scalability and real-world integration of AI applications[9].

AI FOR RISK STRATIFICATION AND DISEASE PREDICTION

ML models have demonstrated the ability to predict MASLD progression using longitudinal data. For example, fibrosis prediction using SVM and RF algorithms allows for patient stratification by fibrosis stage, facilitating personalized disease management[8].

Model training and validation are often enhanced through transfer learning techniques. Pretrained CNNs, such as ResNet and VGG, are fine-tuned on liver-specific imaging datasets to improve diagnostic accuracy and reduce computational costs[9].

Integration of AI models into clinical workflows has followed several strategies. In rule-based systems, ML outputs—such as fibrosis probability scores—are mapped to established clinical fibrosis categories (F0–F4). Hybrid AI–clinical models combine algorithmic predictions with clinician input, such as incorporating a radiologist's elastography interpretation for platelet-independent fibrosis staging[8]. Furthermore, AI-supported real-time decision tools are emerging. For instance, point-of-care ultrasound paired with AI can instantly grade hepatic steatosis[9], while automated laboratory data analysis can flag high-risk patients for further assessment[2].

Finally, AI systems increasingly incorporate metabolic risk factors—including insulin resistance, lipid profiles, and genetic markers—to provide a holistic assessment of MASLD risk and progression[12].

CLINICAL IMPLEMENTATION FEASIBILITY

While AI tools for MASLD show diagnostic promise, real-world adoption depends on overcoming infrastructural and regulatory barriers. EHR-integrated models (*e.g.*, automated FIB-4 calculators) are most feasible, whereas imaging AI requires PACS interoperability and radiologist oversight. Prioritizing use cases with clear region of interest (*e.g.*, fibrosis triage) and investing in clinician-AI collaboration frameworks will accelerate implementation. Prospective trials validating cost-effectiveness (*e.g.*, reduced biopsy rates) are critical for reimbursement and scaling.

CHALLENGES AND LIMITATIONS

Despite advancements and AI promise in MASLD diagnosis, key challenges persist, as technically, data heterogeneity and computational demands limit scalability, while ethical concerns such as algorithmic bias and patient privacy require rigorous governance. Regulatory pathways remain nascent, with few AI tools achieving United States Food and Drug Administration (FDA) clearance. Addressing these challenges necessitates collaborative efforts among developers, clinicians, and policymakers to ensure equitable, effective AI implementation. Variability in datasets limits model generalizability[6]. Challenges include ensuring model interpretability (*via* SHAP) and compliance with regulatory standards for real-world deployment[3]. For validation, most studies are retrospective, so prospective multicenter real-world trials are necessary[7].

Table 1 Artificial intelligence -based models for metabolic dysfunction-associated steatotic liver disease diagnosis and their performance

Ref.	AI model	Data used	Key finding	AUC/performance
Yu *et al*[3], 2025	RF	50 clinical and biochemical features (*e.g.*, BMI, liver enzymes, metabolic markers); validated against histology or elastography in subsets of cohorts	Developed an explainable 10-feature RF model for MASLD prediction	AUC: 0.928 (internal), 0.918 (external)
Wakabayashi *et al*[8], 2025	SVM	Clinical and laboratory markers (excluding platelet counts); validated against histology or elastography in subsets of cohorts	Predicted fibrosis stages without platelet count or elastography	AUC: 0.886 (≥ F2), 0.916 (cirrhosis)
Byra *et al*[9], 2022	CNN (ultrasound)	Applied CNNs to ultrasound images for steatosis detection	Deep learning-based fat quantification using transfer learning	AUC: 0.91 (PDFF ≥ 5%)
Yasaka *et al*[10], 2018	DL (CT)	Utilized CT-based DL for fibrosis staging; referenced biopsy-confirmed fibrosis stages for model validation	Staged liver fibrosis from CT scans (moderate correlation with histopathology)	Moderate performance (needs improvement)

AI: Artificial intelligence; MASLD: Metabolic dysfunction-associated steatotic liver disease; RF: Random forest; BMI: Body mass index; SVM: Support vector machine; CNN: Convolutional neural network; CT: Computed tomography; DL: Deep learning; PDFF: Proton density fat fraction; AUC: Area under curve.

FUTURE DIRECTIONS

The path to AI adoption in MASLD hinges on rigorous validation, regulatory compliance, and seamless clinical integration. Prospective trials to compare AI-driven diagnosis (*e.g.*, CNN-based United States analysis) against liver biopsy in a multicenter cohort must be adopted as a benchmark for AI against gold standards. While regulatory bodies should prioritize transparent, generalizable models.

Global harmonization and collaborative efforts—align FDA (United States), European Medicines Agency (European Union), and Pharmaceuticals and Medical Devices Agency (Japan) guidelines to streamline approvals as by IMDRF's AI Working Group, and integration into clinical guidelines—through consensus statements to endorse AI tools for specific use cases, as example, first-line steatosis screening in T2DM patients, or flag high-risk patients (*e.g.*, F2 fibrosis) for hepatology referral. Meanwhile, mobile AI solutions can bridge resource gaps, ensuring equitable access. A phased rollout (Figure 1) from pilot studies to global scaling will maximize impact while mitigating risks.



Figure 1 Phase implementation of artificial intelligence in metabolic dysfunction-associated steatotic liver disease care roadmap. AI: Artificial intelligence; MASLD: Metabolic dysfunction-associated steatotic liver disease.

CONCLUSION

AI holds transformative potential in MASLD diagnosis, offering high accuracy, cost efficiency, and non-invasive alternatives to liver biopsy. ML and DL models excel in risk prediction, imaging analysis, and fibrosis staging, yet require further validation and standardization. Future research should prioritize explain-ability, multicenter collaboration, and integration into clinical workflows to optimize patient outcomes. Continued advancements in AI-driven hepatology will pave the way for more precise and personalized MASLD management. Most studies adopted a hybrid approach, integrating laboratory, imaging, and (when available) histological data to optimize model performance. However, heterogeneity in data sources underscores the need for standardized multimodal datasets in future research.

FOOTNOTES

Author contributions: Hegazy MA design and wrote the whole mini review.

Conflict-of-interest statement: The author declares no potential conflict of interest with respect to the research, authorship, and/or publication of this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: Egypt

ORCID number: Mona Abd-Elmonem Hegazy 0000-0001-9002-2868.

S-Editor: Liu JH
L-Editor: A
P-Editor: Lei YY

REFERENCES

1 **Arab JP**, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. *Ann Hepatol* 2020; **19**: 674-690 [*RCA*] [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [FullText]

2 **Zhu G**, Song Y, Lu Z, Yi Q, Xu R, Xie Y, Geng S, Yang N, Zheng L, Feng X, Zhu R, Wang X, Huang L, Xiang Y. Machine learning models for predicting metabolic dysfunction-associated steatotic liver disease prevalence using basic demographic and clinical characteristics. *J Transl Med* 2025; **23**: 381 [*RCA*] [PMID: 40155991 DOI: 10.1186/s12967-025-06387-5] [FullText] [Full Text(PDF)]

3 **Yu Y**, Yang Y, Li Q, Yuan J, Zha Y. Predicting metabolic dysfunction associated steatotic liver disease using explainable machine learning methods. *Sci Rep* 2025; **15**: 12382 [*RCA*] [PMID: 40216893 DOI: 10.1038/s41598-025-96478-6] [FullText]

4 **Canbay A**, Kälsch J, Neumann U, Rau M, Hohenester S, Baba HA, Rust C, Geier A, Heider D, Sowa JP. Non-invasive assessment of NAFLD as systemic disease-A machine learning perspective. *PLoS One* 2019; **14**: e0214436 [*RCA*] [PMID: 30913263 DOI: 10.1371/journal.pone.0214436] [FullText] [Full Text(PDF)]

5 **Yip TC**, Ma AJ, Wong VW, Tse YK, Chan HL, Yuen PC, Wong GL. Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. *Aliment Pharmacol Ther* 2017; **46**: 447-456 [*RCA*] [PMID: 28585725 DOI: 10.1111/apt.14172] [FullText]

6 **Ahn JC**, Connell A, Simonetto DA, Hughes C, Shah VH. Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases. *Hepatology* 2021; **73**: 2546-2563 [*RCA*] [PMID: 33098140 DOI: 10.1002/hep.31603] [FullText]

7 **Spann A**, Yasodhara A, Kang J, Watt K, Wang B, Goldenberg A, Bhat M. Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review. *Hepatology* 2020; **71**: 1093-1105 [*RCA*] [PMID: 31907954 DOI: 10.1002/hep.31103] [FullText]

8 **Wakabayashi SI**, Kimura T, Tamaki N, Iwadare T, Okumura T, Kobayashi H, Yamashita Y, Tanaka N, Kurosaki M, Umemura T. AI-Based Platelet-Independent Noninvasive Test for Liver Fibrosis in MASLD Patients. *JGH Open* 2025; **9**: e70150 [*RCA*] [PMID: 40191781 DOI: 10.1002/jgh3.70150] [FullText] [Full Text(PDF)]

9 **Byra M**, Han A, Boehringer AS, Zhang YN, O'Brien WD Jr, Erdman JW Jr, Loomba R, Sirlin CB, Andre M. Liver Fat Assessment in Multiview Sonography Using Transfer Learning With Convolutional Neural Networks. *J Ultrasound Med* 2022; **41**: 175-184 [*RCA*] [PMID: 33749862 DOI: 10.1002/jum.15693] [FullText]

10 **Yasaka K**, Akai H, Kunimatsu A, Abe O, Kiryu S. Deep learning for staging liver fibrosis on CT: a pilot study. *Eur Radiol* 2018; **28**: 4578-4585 [*RCA*] [PMID: 29761358 DOI: 10.1007/s00330-018-5499-7] [FullText]

11 **Masaebi F**, Azizmohammad Looha M, Mohammadzadeh M, Pahlevani V, Farjam M, Zayeri F, Homayounfar R. Machine-Learning Application for Predicting Metabolic Dysfunction-Associated Steatotic Liver Disease Using Laboratory and Body Composition Indicators. *Arch Iran Med* 2024; **27**: 551-562 [*RCA*] [PMID: 39492562 DOI: 10.34172/aim.31269] [FullText]

12 **Perveen S**, Shahbaz M, Keshavjee K, Guergachi A. A Systematic Machine Learning Based Approach for the Diagnosis of Non-Alcoholic Fatty Liver Disease Risk and Progression. *Sci Rep* 2018; **8**: 2112 [*RCA*] [PMID: 29391513 DOI: 10.1038/s41598-018-20166-x] [FullText] [Full Text(PDF)]

Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: office@baishideng.com
Help Desk: https://www.f6publishing.com/helpdesk
https://www.wjgnet.com

© 2025 Baishideng Publishing Group Inc. All rights reserved.